Single application head lice product capable of killing both eggs and lice.

Mr Hugh Alsop

Hugh Alsop.JPG

Mr Alsop was appointed Chief Executive Officer of Hatchtech Pty Ltd in March 2013.   Hugh has over 16 years’ experience in the pharmaceutical and biotechnology industries and holds a Bachelor of Science with Honours (in Chemistry) from the University of Melbourne and an MBA from the Melbourne Business School.   He joined Hatchtech from Phosphagencis Ltd, where he was Vice President of Operations and Business Development and was responsible for the company’s opioid transdermal patch development programs. 

Prior to Phosphagenicis, Hugh was Director of Business Development at Acrux Limited from 2006-2012, where his highlight achievement was his role in the Axiron® licensing to Eli Lilly in March 2010.  At the time this was the largest single product licensing deal by an Australian biotech company, with $335 million in potential milestone payments and a significant royalty stream.  Axiron was subsequently approved for use by the FDA.

Prior to Acrux, Mr Alsop was responsible for successfully expanding Sigma Pharmaceuticals’ export markets in Europe and Asia completing a number of out-licensing, manufacturing and distribution agreements.  He was also responsible for the commercial aspects of Sigma's contract manufacturing business, focusing on maximizing existing relationships and seeking new growth opportunities.  Prior to Sigma he spent eight years at Mayne Pharma (formerly Faulding Pharmaceuticals) in a variety of roles.

Latest News

Oct 21, 2014 Hatchtech Announces Successful Results from Phase 2 Ovicidal Study

Sep 02, 2014 Hatchtech Announces Successful Phase 3 Results

Dec 11, 2013 Hatchtech Receives SPA and Announces Patent Grants

Oct 31, 2013 Hatchtech Completes $12.6m Capital Raise, Secures Funds for Phase III and NDA Submission